Johnson & Johnson (JNJ) said Monday that new data from an indirect treatment comparison showed consistent and sustained disease control with its drug Imaavy versus other approved FcRn blockers in adults with generalized myasthenia gravis.

Generalized myasthenia gravis is a rare autoimmune disorder that leads to severe muscle weakness.

The study compared all published phase 3 data of the treatments, the company said.

According to the study, Imaavy showed comparable symptom relief at week 1 and consistent and sustained disease control with greater or "statistically significant improvement" in standardized assessment scores versus the published phase 3 data of other marketed FcRn blockers at several intervals for up to 24 weeks, the company said.